Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, we found two genetic/clinical correlations that must be evaluated to understand their impact in the clinical setting: i) how is PTEN deletion a favorable prognostic factor in GBM IDH wildtype and an unfavorable prognostic factor in astrocytoma IDH wildtype and ii) how EGFR amplification is an independent and strong factor of response to radiotherapy.
|
31623593 |
2019 |
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IDH-wild-type (wt) infiltrating astrocytomas are mostly primary GBMs and are characterized by EGFR, PTEN, TP53, NF1, RB1, PDGFRA, and CDKN2A/B alterations, TERT-p mutations, and characteristic copy number alterations including gains of chromosome 7 and losses of 10.
|
29521646 |
2018 |
Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
NGS data obtained in a retrospective analysis of 121 gliomas allowed for their molecular classification into distinct biological groups, including (i) isocitrate dehydrogenase gene (IDH) 1 or 2 mutant astrocytic gliomas with frequent α-thalassemia/mental retardation syndrome X-linked (ATRX) and tumor protein p53 (TP53) gene mutations, (ii) IDH mutant oligodendroglial tumors with 1p/19q codeletion, telomerase reverse transcriptase (TERT) promoter mutation and frequent Drosophila homolog of capicua (CIC) gene mutation, as well as (iii) IDH wildtype glioblastomas with frequent TERT promoter mutation, phosphatase and tensin homolog (PTEN) mutation and/or epidermal growth factor receptor (EGFR) amplification.
|
26919320 |
2017 |
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytoplasmic accumulation of EGFR protein was detected in 75% of astrocytomas, and 21% of the astrocytomas showed nuclear localization (p=0.003).
|
24170555 |
2014 |
Astrocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It has been reported that vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), cyclin D1 and progesterone receptor (PR) expression levels are elevated in patients with high-grade astrocytomas.
|
22542550 |
2012 |
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The study analysed INA, nestin, Olig2 and p53 expression, loss of heterozygosity of microsatellite markers from telomere to centromere of 10p, 10q, 1p and 19q chromosomes and epidermal growth factor receptor gene (EGFR) amplification in 40 gliomas (five astrocytomas, 12 oligodendrogliomas, 11 oligoastrocytomas, 12 glioblastomas).
|
21653654 |
2011 |
Astrocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aims of the research reported here were (1) to evaluate the Cx43 protein and mRNA of both low histological grade and high histological grade astrocyte tumors; (2) to evaluate if the immunohistochemistry of the Cx43 protein in astrocytomas could be correlated to histological grade, to proliferative activity (Ki67/Mib1-index) and to immunolabelling of the epidermal growth factor receptor (EGFR); (3) to evaluate if the reduction in levels of the Cx43 protein correlates with reduction in levels of the Cx43 mRNA.
|
19604543 |
2010 |
Astrocytoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
A reduction of epidermal growth factor receptor is involved in brefelamide-induced inhibition of phosphorylation of ERK in human astrocytoma cells.
|
19559020 |
2009 |
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR) amplification and PTEN loss are two common genetic alterations seen in GBM but not in lower-grade astrocytomas that could be responsible for TF up-regulation.
|
19276385 |
2009 |
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGFR is a key component of autonomous growth signaling in several tumors, and correlates with the malignancy grade of astrocytoma.
|
19515085 |
2009 |
Astrocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, annexin-1 upregulation in astrocytomas may contribute to tumor progression and its expression profile is similar to its substrate, EGFR, suggesting a possible regulation thereof.
|
19767728 |
2009 |
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These suggest that the tumor proliferation, at least in higher grades of astrocytomas is dependent in some measure on EGF and EGFR-related signaling pathways.
|
19127042 |
2009 |
Astrocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We observed that the expression of LRIG1 was decreased, while the expression of EGFR was increased in the majority of astrocytomas, and the ratio of EGFR/LRIG1 was increased by sixfold in tumors versus corresponding non-neoplastic tissue.
|
19300910 |
2009 |
Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that modulation of the EGFR c.2073A>T polymorphism could play a role in future therapeutic approaches to astrocytoma.
|
18949739 |
2009 |
Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
In particular, high-grade astrocytomas (that is, AAs and GBMs) had elevated fractions of tumor cells with polysomy of chromosome 7 and the EGFR locus and monosomy of chromosome 10 and the PTEN locus.
|
18240930 |
2008 |
Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In particular, high-grade astrocytomas (that is, AAs and GBMs) had elevated fractions of tumor cells with polysomy of chromosome 7 and the EGFR locus and monosomy of chromosome 10 and the PTEN locus.
|
18240930 |
2008 |
Astrocytoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Prognostic significance of co-overexpression of the EGFR/IGFBP-2/HIF-2A genes in astrocytomas.
|
17285230 |
2007 |
Astrocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The markers p53 and MIB-1 were significantly higher expressed in astrocytomas than in oligodendrogliomas and expression levels of p53 and EGFR were inversely associated within the astrocytic group.
|
17390041 |
2007 |
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGFR protein was detected in 29 % of low grade and in 60 % of high grade astrocytomas.
|
17822324 |
2007 |
Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Concurrent EGFR amplification and TP-53 mutation in glioblastomas.
|
17907599 |
2007 |
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the activation status of these 3 signaling molecules as well as wild-type (EGFRwt) and mutant (EGFRvIII) EGFR in 82 malignant astrocytic gliomas (55 glioblastomas and 27 anaplastic astrocytomas) using immunohistochemistry.
|
17146292 |
2006 |
Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
EGFR overexpression is the most frequent and important molecular event in the development of astrocytic gliomas, and the P13K signaling pathway is one of the most important downstream pathways of EGFR.
|
16700623 |
2006 |
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGFR intragenic loss and gene amplification in astrocytic gliomas.
|
16364761 |
2006 |
Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chromogenic in situ hybridization (CISH) was used to detect amplification of the epidermal growth factor receptor (EGFR) gene in tissue microarrays of tumours derived from 287 patients with grade II-IV diffuse astrocytomas.
|
16866989 |
2006 |
Astrocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas.
|
16133418 |
2005 |